Skip to main content
Premium Trial:

Request an Annual Quote

One Biosciences: Hedi Ben Brahim

Hedi Ben Brahim has been appointed as CEO of single-cell analysis firm One Biosciences, succeeding Magali Richard, who cofounded the company and will remain its chief operating officer. Ben Brahim joins Paris-based One Biosciences from Transgene, where he was CEO. Prior to that, he was VP of immunotherapy at Institut Mérieux. He holds degrees from École Polytechnique and from École Nationale Supérieure des Mines de Paris.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.